Gary Lichtenstein, MD
Gastroenterology · Philadelphia, PANPI 1700890720
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $251,481 of the $342,389 with a category attached, or 73.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 15.6%. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $1332.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$53K
- Janssen Scientific Affairs, LLC$48K
- Pfizer$44K
- AbbVie$38K
- Johnson & Johnson$37K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- plus $101K from 14 others
Across 33 payments — averaging $1352.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$44K
- UCB, Inc.$820
What the payments were for
- Consulting fees$251,48173%
- Speaking & faculty fees$57,98117%
- Travel & lodging$27,6288%
- Food & beverage$4,6511%
- Education$6480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 12 | $53,465 |
| Janssen Scientific Affairs, LLC | 54 | $47,563 |
| Pfizer | 22 | $43,901 |
| AbbVie | 27 | $38,452 |
| Johnson & Johnson | 36 | $37,207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $20,691 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $16,416 |
| E.r. Squibb & Sons, L.L.C. | 8 | $14,674 |
| Celltrion USA Inc. | 13 | $13,230 |
| Endo Pharmaceuticals Inc. | 6 | $9,045 |
| Merck | 9 | $8,954 |
| Bristol Myers Squibb | 9 | $7,577 |
| Janssen Research & Development, LLC | 7 | $6,840 |
| UCB SA | 2 | $5,250 |
| Lilly USA, LLC | 2 | $4,950 |
| UCB, Inc. | 2 | $4,500 |
| Sandoz | 1 | $3,625 |
| Fresenius Kabi USA, LLC | 1 | $3,050 |
| Gilead | 1 | $2,990 |
| ERBE USA Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$342,389 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 149 | $3,867,105 |
| Humira(Cf) PenAdalimumab | 75 | $571,613 |
| Skyrizi On-BodyRisankizumab-Rzaa | 26 | $522,510 |
| Humira(Cf)Adalimumab | 12 | $161,685 |
| Entyvio PenVedolizumab | 14 | $78,114 |
| Mesalamine | 121 | $63,948 |
| CreonLipase/Protease/Amylase | 12 | $27,586 |
| Colestipol Hcl | 53 | $7,197 |
| Balsalazide Disodium | 15 | $2,216 |
| LoperamideLoperamide Hcl | 24 | $1,459 |
| Esomeprazole Magnesium | 28 | $1,284 |
| Famotidine | 54 | $900 |
| Omeprazole | 73 | $826 |
| Lansoprazole | 22 | $750 |
| Dicyclomine Hcl | 15 | $597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $37,207 | $3,867,105149 claims |
| AbbVieHumira(Cf), Creon | $38,452 | $189,27224 claims |
| SandozLansoprazole | $3,625 | $75022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Philadelphia
- Michael KochmanPhiladelphia$361K
- Gregory GinsbergPhiladelphia$234K
- Neilanjan NandiPhiladelphia$209K
- David LichtensteinPhiladelphia$192K
- Alexander SchlachtermanPhiladelphia$188K
- Kuchikala ReddyPhiladelphia$182K
- James LewisPhiladelphia$175K
- Beth GardnerPhiladelphia$122K
- Gary FalkPhiladelphia$121K
- Adam EhrlichPhiladelphia$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.